| [2] |
Le A-L, Huang G, Goddard Y, et al. The cost of chronic pelvic pain in women:a systematic review of the literature[J]. J Obstet Gynaecol Canada, 2021, 43(5):655-656.
|
| [3] |
冷金花. 女性慢性盆腔疼痛的研究进展[C]// 第十三届妇产科学新进展学术大会论文集,厦门, 2017.
|
| [4] |
Hutton D, Mustafa A, Patil S, et al. The burden of chronic pelvic pain (CPP):costs and quality of life of women and men with CPP treated in outpatient referral centers[J]. PLoS One, 2023, 18(2):e0269828. DOI: 10.1371/journal.pone.0269828.
Chronic Pelvic Pain (CPP) is a complex, multifaceted condition that affects both women and men. There is limited literature on the cost utilization the healthcare system and CPP patients incur. The purpose of this analysis is to characterize the overall healthcare utilization, cost burden, and quality-of-life restrictions experienced by CPP patients using data from an outpatient pelvic rehabilitation practice.
|
| [5] |
Daniels JP, Khan KS. Chronic pelvic pain in women[J]. BMJ, 2010, 341:c4834. DOI: 10.1136/bmj.c4834.
|
| [6] |
Apte G, Nelson P, Brismée JM, et al. Chronic female pelvic pain--part 1:clinical pathoanatomy and examination of the pelvic region[J]. Pain Pract, 2012, 12(2):88-110. DOI: 10.1111/j.1533-2500.2011.00465.x.
Chronic pelvic pain is defined as the presence of pain in the pelvic girdle region for over a 6‐month period and can arise from the gynecologic, urologic, gastrointestinal, and musculoskeletal systems. As 15% of women experience pelvic pain at some time in their lives with yearly direct medical costs estimated at $2.8 billion, effective evaluation and management strategies of this condition are necessary. This merits a thorough discussion of a systematic approach to the evaluation of chronic pelvic pain conditions, including a careful history‐taking and clinical examination. The challenge of accurately diagnosing chronic pelvic pain resides in the degree of peripheral and central sensitization of the nervous system associated with the chronicity of the symptoms, as well as the potential influence of the affective and biopsychosocial factors on symptom development as persistence. Once the musculoskeletal origin of the symptoms is identified, a clinical examination schema that is based on the location of primary onset of symptoms (lumbosacral, coccygeal, sacroiliac, pelvic floor, groin or abdominal region) can be followed to establish a basis for managing the specific pain generator(s) and manage tissue dysfunction.
|
| [7] |
Reavey J, Vincent K. Chronic pelvic pain[J]. Obstet Gynaecol Reprod Med, 2022, 32(1):8-13.
|
| [8] |
Zaurito A, Mehmeti I, Limongelli F, et al. Natural compounds for endometriosis and related chronic pelvic pain:A review[J]. Fitoterapia, 2024, 179:106277. DOI: 10.1016/j.fitote.2024.106277.
|
| [13] |
中华预防医学会生殖健康分会, 中国医师协会妇产科医师分会子宫内膜异位症学组. 子宫内膜异位症疼痛管理指南(2024年实践版)[J]. 中国实用妇科与产科杂志, 2024, 40(1):50-61. DOI: 10.19538/j.fk2024010114.
|
| [16] |
Centemero A, Rigatti L, Giraudo D, et al. The role of the multi-disciplinary team and multi-disciplinary therapeutic protocol in the management of the chronic pelvic pain:There is strength in numbers![J]. Arch Ital Urol Androl, 2021, 93(2):211-214. DOI: 10.4081/aiua.2021.2.211.
Introduction: The aim of the study is to evaluate the effectiveness of a Multi-disciplinary team (MDT) and multi-disciplinary approach in the treatment of Chronic Pelvic Pain (CPP). Methods: The data of all consecutive patients referred for a CPP from 11/2016 to 2/2019 has been prospectively collected. The sample was divided in two groups: Group A, made by patients managed after the institution of our MDT, and Group B, made of patients managed before this date. The MDT is composed by three urogynecologists, a psychologist and a physiotherapist. All Group A patients underwent a weekly bladder instillation with dimethyl sulfoxide (DMSO), kinesiotherapy for trigger points and Percutaneous Tibial Nerve Stimulation for 10 consecutive weeks. Patients were asked to perform a self-treatment following the Stanford Protocol and to adhere to a specific diet. All Group B patients were managed only with DMSO instillations and a strict diet. Results: The Group A was made of 41 females and 6 males while the Group B was made of 38 females and 5 males. The Group A patients showed a statistically significant improvement in the Pelvic Pain Urgency Frequency, in the frequency times reported at the 6 months voiding diary, and a better Patient Global Impression of Improvement. Conclusions: Our data support the efficacy of the MDT in the management of CPP. The multimodal approach might represent an effective and reproducible non-invasive option to manage successfully CPP.
|
| [17] |
Allaire C, Yong PJ, Bajzak K, et al. Guideline No. 445:management of chronic pelvic pain[J]. J Obstet Gynaecol Can, 2024, 46(1):102283. DOI: 10.1016/j.jogc.2023.102283.
|
| [18] |
Yu J, Berga SL, Zou E, et al. Neurotrophins and their receptors,novel therapeutic targets for pelvic pain in endometriosis,are coordinately regulated by IL-1β via the JNK signaling pathway[J]. Am J Pathol, 2023, 193(8):1046-1058. DOI: 10.1016/j.ajpath.2023.04.007.
|
| [19] |
García-Izquierdo L, Marín-Sánchez P, García-Peñarrubia P, et al. New potential pharmacological options for endometriosis associated pain[J]. Int J Mol Sci, 2024, 25(13):7068. DOI: 10.3390/ijms25137068.
Endometriosis is a chronic inflammatory disorder characterized by the abnormal growth of endometrial-like tissue outside the uterine cavity, affecting 10–15% of women of reproductive age. Pain is the most common symptom. Treatment options include surgery, which has limited effectiveness and high recurrence rates, and pharmacotherapy. Hormonal therapies, commonly used for symptom management, can have side effects and contraceptive outcomes, contributing to the infertility associated with endometriosis, with pain and lesions often reappearing after treatment cessation. Among its etiological factors, immunological and inflammatory dysregulation plays a significant role, representing an interesting target for developing new therapeutic strategies. This review critically analyzes recent studies to provide an updated synthesis of ongoing research into potential new pharmacotherapies focusing on lesion progression, pain relief, and improving quality of life. Immunotherapy, natural anti-inflammatory and antioxidant compounds and drug repurposing show promise in addressing the limitations of current treatments by targeting immunological factors, potentially offering non-invasive solutions for managing pain and infertility in endometriosis. Promising results have been obtained from in vitro and animal model studies, but clinical trials are still limited. More effort is needed to translate these findings into clinical practice to effectively reduce disease progression, alleviate pain symptoms and preserve the reproductive capacity, improving patients’ overall wellbeing.
|